LASP1 and melanoma: Notably, these results, demonstrating loss of LASP1 expression in the course of melanoma progression, are all based on the presence of LASP1 in the cytoplasm since nuclear LASP1 staining, which is characteristic for many aggressive LASP1-positive tumors (breast, prostate and liver carcinoma, medulloblastoma [4, 32, 41, 42]) was not observed in any of the melanocytic tumor samples (Table 1).